Biogen (BIIB) exec says they expect 2026 sales for MS products, excluding Vumerity to decline by the mid teen percentages

Biogen (BIIB) exec says they expect 2026 sales for MS products, excluding Vumerity to decline by the mid teen percentages.

Biogen’s executive guidance projecting a mid-teen percentage decline in sales for MS products (excluding Vumerity) by 2026 is a concerning signal for the company. This likely suggests challenges in maintaining market share or pricing power, which could weigh heavily on investor sentiment and future earnings expectations. Consequently, the forecast may also prompt downward revisions to consensus estimates, influencing valuation and positioning within the biotechnology sector.